H. Michael Shepard

H. Michael Shepard is an American scientist and inventor known for his work in the field of cancer research. He is best known for his role in the discovery and development of the monoclonal antibody drug Herceptin, which is used to treat certain types of breast and gastric cancers.

Herceptin, also known as trastuzumab, is a monoclonal antibody drug that targets the HER2 protein. It is used in the treatment of HER2-positive breast and gastric cancers, and has been shown to significantly improve survival rates in patients with these types of cancer.

H. Michael Shepard played a key role in the discovery and development of Herceptin. He was part of a team of scientists at Genentech who identified and characterized the HER2 protein as a potential target for cancer therapy. Shepard was instrumental in the design and engineering of Herceptin, which specifically targets the HER2 protein and has been proven to be effective in treating HER2-positive cancers.

Yes, H. Michael Shepard has received numerous awards and recognition for his contributions to cancer research. He was named a Fellow of the American Association for Cancer Research in 2011 and received the Jacob Heskel Gabbay Award in Biotechnology and Medicine in 2013. Shepard was also elected to the National Academy of Inventors in 2016.

As of the information available, H. Michael Shepard is currently the Chief Scientific Officer and Executive Vice President of Antibody Therapeutics at Halozyme Therapeutics, a biotechnology company. In his current role, he focuses on the development of innovative antibody-based therapies for cancer and other diseases.